^
    Back
    Association details:
    Biomarker:PD-L1 underexpression
    Cancer:Gastric Adenocarcinoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma

    Published date:
    02/01/2022
    Excerpt:
    These data suggest the lack of benefit in the addition of ICI to chemotherapy in low PD-L1-expressing GEAC tumors...our analyses fail to demonstrate a survival advantage offered by the addition of ICIs to conventional chemotherapy in patients with low PD-L1–expressing tumors.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.21.01862